Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord DrugsBOM:538965 +1.38%67 Gross Margin % is 9.95% as of Mar. 2026, which is 46% below its 10-year median of 18.59. GuruFocus rates BOM:538965 with a GF Score™ of 67/100 and a GF Value™ of ₹60.93 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 943 Drug Manufacturers companies, Concord Drugs ranks worse than 94.27% on this metric.
Concord Drugs Ltd gross margin has been in long-term decline. The average rate of decline per year is -3.5%.
The historical rank and industry rank for Concord Drugs's Gross Margin % or its related term are showing as below:
BOM:538965'
s Gross Margin % Range Over the Past 10 Years
Min: 14.09 Med: 18.59 Max: 28.53
Current: 14.09
During the past 13 years, the highestGross Margin % of Concord Drugs was 28.53%. The lowest was 14.09%. And the median was 18.59%.
BOM:538965's Gross Margin % is ranked worse than 94.27% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:538965: 14.09
Concord Drugs had a gross margin of 9.95% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Concord Drugs was -3.50% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Concord Drugs had a gross margin of 9.95% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Concord Drugs Gross Margin % Related Terms
Concord Drugs Gross Margin % Historical Data
* Premium members only.
The historical data trend for Concord Drugs's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Drugs Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Concord Drugs's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Concord Drugs (BOM:538965) has a Gross Margin % of 9.95% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Concord Drugs and its competitors. This is 46% below median its historical median of 18.59. Over the past decade, Concord Drugs' Gross Margin % has ranged from 14.09 to 28.53. According to the industry distribution chart, Concord Drugs ranks #889 out of 943 companies in the Drug Manufacturers industry, placing it in the top 94.3%.
Is Concord Drugs' Gross Margin % too high?
Concord Drugs' current Gross Margin % of 9.95% is 46% below median its 10-year median of 18.59. Over the past 10 years, this metric has ranged from a low of 14.09 to a high of 28.53. The Drug Manufacturers industry median Gross Margin % is 48.54. Concord Drugs' value of 9.95% is 79.5% below this industry median. Based on the distribution chart, Concord Drugs ranks #889 out of 943 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Concord Drugs has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Concord Drugs ranks #889 out of 943 companies for Gross Margin %. This places Concord Drugs in the lower half of its industry. The industry median Gross Margin % is 48.54. Concord Drugs' value of 9.95% is 79.5% below this benchmark. Historically, Concord Drugs' own Gross Margin % has ranged from 14.09 to 28.53 over the past decade. While the company's 10-year median is 18.59 vs. the industry median of 48.54, Concord Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Drugs's current Gross Margin % of 9.95% is 79.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Concord Drugs and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Drugs's current Gross Margin % is 9.95%, which is 46% below median its own 10-year median of 18.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.93, compared to a current price of ₹71.23 — trading 16.9% above its estimated fair value. The current Gross Margin % is 9.95%, which is 46% below median its 10-year median of 18.59 and 79.5% below the Drug Manufacturers industry median of 48.54. Concord Drugs' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Gross Margin % is 9.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Drugs (BOM:538965) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued.
The current stock price of ₹71.23 is trading 16.9% above its estimated GF Value™ of ₹60.93.
GuruFocus considers Concord Drugs to be Modestly Overvalued.
Key valuation signals for BOM:538965:
Gross Margin %: 9.95% (46% below median its 10-year median of 18.59)
GF Value™: ₹60.93 vs. price of ₹71.23 (16.9% above fair value)
Industry Position: 79.5% below the Drug Manufacturers median (#889 of 943)
No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score
Get the complete analysis for BOM:538965
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538965 has been successfully added to your 
